Myelodysplastic syndrome transformation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Myelodysplastic syndrome transformation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia https://clinicaltrials.eu/trial/study-of-s227928-alone-and-with-venetoclax-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-myelodysplastic-syndrome-or-chronic-myelomonocytic-leukemia/ Wed, 29 Apr 2026 15:03:59 +0000 https://clinicaltrials.eu/trial/study-of-s227928-alone-and-with-venetoclax-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-myelodysplastic-syndrome-or-chronic-myelomonocytic-leukemia/ This clinical trial is focused on studying the effects of a new treatment for certain types of blood cancers. The diseases being studied include Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Chronic Myelomonocytic Leukemia (CMML). The treatment involves a new medication called S227928, which is an anti-CD74 antibody-drug conjugate. This means it is a special type of medicine designed to target and attack cancer cells. The study will also look at how S227928 works when used alone and when combined with another medication called Venetoclax, which is already used to treat some types of blood cancers.

The purpose of this study is to understand how safe and effective S227928 is for patients with these specific blood cancers, especially those whose disease has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will focus on finding the safest dose of S227928 and how well patients tolerate it, both on its own and in combination with Venetoclax. In the second phase, the study will evaluate how well the combination of S227928 and Venetoclax works in fighting the cancer.

Participants in the study will receive the treatment and be monitored closely by healthcare professionals. The treatment will be given either as a tablet or through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study aims to gather important information about the treatment’s effects on the body, including any side effects and how the body processes the medication. This information will help determine if S227928 could be a beneficial treatment option for patients with these challenging blood cancers.

]]>